FIND
Diagnosis for all







2025 Activity report

We remain committed to a future in which no one is left behind because they could not access the right test at the right time.

Leadership message

In 2025, amid an increasingly challenging global funding environment, FIND remained focused on a simple but urgent purpose: ensuring that everyone, everywhere has access to a diagnostic test where required or when needed. Thanks to the commitment of our donors, partners and colleagues, we continued to turn diagnostic innovation into practical, measurable value for the people and health systems that need it most.

That impact is substantial. **FIND-supported more than 50 million diagnostic products** which were distributed globally across COVID-19, Ebola, HIV, malaria and fever, human African trypanosomiasis (HAT) and tuberculosis (TB). We estimate that this access helped avert approximately **5 million disability-adjusted life years** and generated around **US$ 21 billion in societal value** through health gains – demonstrating the extraordinary return that investment in diagnosis can deliver.

Behind these numbers is a broader transformation. Across TB, and other communicable and noncommunicable diseases (NCDs), pandemic threats, and antimicrobial resistance (AMR), FIND advanced point-of-care and near-point-of-care solutions designed to reach underserved communities. We generated clinical and operational evidence to guide policy review, improve products, and support country adoption – helping decision-makers understand not only which tools work, but where and under what conditions they can deliver the greatest benefit.

We also invested in the capabilities that make access sustainable. The FIND Training Academy enrolled **850 learners**, while in-person training conducted in Kenya and Malawi strengthened practical skills in laboratory systems, sample referral and supply-chain management. Through target product profiles, National Essential Diagnostic Lists (NEDLs), diagnostic network optimization (DNO) and market-shaping initiatives, we helped countries move from evidence to implementation and make quality diagnostics more affordable, available and usable within routine health services.

Digital and AI-enabled tools continued to support this work – from sample-referral tracking and network optimization to AI-enabled screening pilots. Our priority has remained consistent: strengthen country ownership and equip national programmes with practical tools to make faster, better-informed decisions.

We achieved this progress while making difficult choices. In response to funding constraints, we strengthened financial discipline, aligned expenditure more closely with available resources and prioritized the work with the greatest potential to protect impact. This stewardship is essential to maintaining the trust of the donors and partners who make our mission possible and work alongside us.

As we look ahead, the need is clear. Too many people still suffer from preventable illness and death because a reliable diagnosis is unavailable, unaffordable or arrives too late. Closing that gap will require sustained investment, stronger partnerships and an unwavering focus on solutions that countries can own and scale.

To our donors, government partners, technical partners, and communities: thank you for your trust and collaboration. To our colleagues across FIND: thank you for your resilience, expertise and determination. Together, we are demonstrating that investing in diagnosis delivers lasting value and stronger health systems, enabling better-informed healthcare and improving lives.



Professor Marcel Tanner
Interim Chair



Dr Jutta Reinhard-Rupp
Chief Executive Officer | Chief Scientific Officer





FIND's impact in 2025 at a glance



MORE THAN 50 MILLION

FIND-SUPPORTED
DIAGNOSTIC PRODUCTS REACHED
PEOPLE AROUND THE WORLD

~5 MILLION

HEALTHY YEARS OF LIFE
PROTECTED THROUGH EARLIER,
IMPROVED DIAGNOSIS

2 COUNTRIES

KENYA AND GUINEA
OFFICIALLY ELIMINATED SLEEPING
SICKNESS (HAT) AS A PUBLIC
HEALTH PROBLEM

86 PRODUCTS

IN FIND'S PORTFOLIO,
FROM RAPID TESTS TO DIGITAL
HEALTH TOOLS



Who we are and why diagnostics matter

FIND is a global non-profit organization dedicated to closing the gaps in access to reliable diagnostic testing, with a particular focus on people in low-and middle-income countries (LMICs) who remain underserved by health systems.

FIND's 2025 portfolio:

86

products supporting better diagnosis worldwide

FIND works in collaboration with governments, partners, scientists, manufacturers, and frontline health workers to design, evaluate, and support the introduction of diagnostic tools, ranging from rapid tests suitable for primary care settings to advanced laboratory systems and digital tools that support surveillance and outbreak response.

In 2025, FIND supported a portfolio of **86 products** across several disease areas including TB, malaria, HIV, hepatitis, sleeping sickness, sexually transmitted infections, drug-resistant infections, and diseases with outbreak potential such as mpox and Lassa fever. Most were diagnostic tests and devices, complemented by digital tools that help health systems use testing tools more effectively.


75

Diagnostic tests and devices

11

Digital health tools

HOW A DIAGNOSTIC TEST CHANGES A PATIENT'S JOURNEY





FIND's work with other PDPs

FIND works with other product development partnerships (PDPs) to ensure that underserved communities have access to essential diagnostic tools and to extend the value of donor investment across the full product lifecycle—from research and development to implementation and equitable access.

These collaborations combine complementary expertise, reduce duplication, and create stronger pathways for new health tools to reach the people who need them.

FIND partners with the Drugs for Neglected Diseases initiative (DNDi) to advance diagnostics for neglected tropical diseases (NTDs) and works with the Global Antibiotic Research & Development Partnership (GARDP) and WHO's STI programme to strengthen the diagnosis and management of sexually transmitted infections. FIND also collaborates with Medicines for Malaria Venture (MMV), TB Alliance, and the International AIDS Vaccine Initiative (IAVI) on joint advocacy for global health R&D financing, equitable access, community engagement and stronger global health policy.



INTEGRATED INNOVATION FOR TB

FIND co-hosted the New TB Tools Working Group meetings with IAVI and TB Alliance during the Union World Conference on Lung Health in Copenhagen. The group brought diagnostics, vaccines and therapeutics communities together to support coordinated investment and acceleration of the development and uptake of complementary tools.

STRONGER SOLUTIONS FOR WOMEN AND NEWBORNS

FIND contributed to a maternal, newborn and women's health working group with TB Alliance, MMV, GARDP, DNDi, the International Vaccine Institute and academic and implementation partners. The collaboration aligns product-development priorities and helps close gaps that no single organization can address alone.

LEADERSHIP ALIGNMENT AND NEW FUNDING OPPORTUNITIES

In November 2025, FIND's CEO met with DNDi's Executive Director to reaffirm the longstanding partnership and identify opportunities for joint funding proposals.

COORDINATION ACROSS THE PDP ECOSYSTEM

In December, FIND's Chief Scientific Officer joined the PDP CEO meeting hosted by the Gates Foundation in New York, helping align priorities and strengthen collaboration across organizations.

CONSISTENT JOINT ADVOCACY

FIND's External Affairs team participates in monthly PDP coordination calls which focus on aligning advocacy, pooling resources and planning shared engagements—amplifying the collective case for sustained global health R&D investment.

Stories from 2025

Kenya and Guinea eliminate sleeping sickness

In July 2025, Kenya officially eliminated human African trypanosomiasis (HAT) – more commonly known as sleeping sickness – as a public health concern. Guinea also achieved the same milestone in 2025. Both results were confirmed by the World Health Organization (WHO).



The disease, transmitted by the tsetse fly, was once a major cause of mortality across parts of Africa. Since 2020, FIND has worked closely with Kenya's Ministry of Health to map health facilities in affected regions, upgrade laboratory equipment, and retrain clinicians and laboratory staff to recognize and treat the disease.

This sustained, multi-year groundwork contributed to the milestone announced in 2025.





Reaching two million people in rural India

With support from the Stop TB Partnership's TB REACH Wave 10 grant, FIND delivered an integrated, community-led model for TB and NCDs screening, diagnosis, and referral across more than 500 underserved communities in northern Karnataka, India, from June 2023 to March 2025.







Nearly **1,130 women from Self-help Affinity Groups** brought services directly to households, prioritizing women, people living in poverty and others facing barriers to facility-based care.

The investment reached almost **1.8 million people**, approximately half of whom were women. It identified about 43,730 people with presumptive TB; 1,580 were diagnosed and started treatment, achieving an 87% treatment success rate. An AI-enabled chest X-ray pilot completed approximately 8,000 scans in seven months, helping identify additional people with TB.

The programme also strengthened TB prevention. Around 7,100 household contacts were screened for TB infection, including approximately 2,370 people tested with Cy-TB. About 1,310 eligible people started preventive therapy, with 93% completing treatment.

Integrating NCD services increased the value of every community contact. More than 936,000 people were screened for diabetes and hypertension, identifying approximately 42,300 people with elevated blood glucose and 49,700 with high blood pressure. Nearly 55,000 were referred for further evaluation, and more than 5,000 started treatment. A further 10,500 TB-negative people with respiratory symptoms were screened for chronic respiratory disease, with over 6,800 linked to care.


Donor funding enabled FIND to translate targeted support into a scalable, equity-focused model with measurable results across TB, NCDs and chronic respiratory disease. By combining trusted women-led community networks, innovative diagnostics and strong referral pathways, the programme extended quality services to people routinely missed by facility-based care.

TB REACH Wave 10 was launched by the Stop TB Partnership in March 2022 with support from Global Affairs Canada, USAID and the UK Foreign, Commonwealth & Development Office.

Making diabetes monitoring available in public clinics

Continuous glucose monitors can transform diabetes management by providing real-time information that helps people maintain safer glucose levels.

Yet these devices remain largely out of reach for patients who rely on public health systems. With donor support, FIND generated evidence in Kenya and South Africa demonstrating that this technology is effective and valued by people living with type 1 diabetes. This evidence is now supporting its introduction in public-sector clinics – helping turn a proven innovation into more equitable access and better care for patients who have previously been left behind.



Responding quickly when new health threats emerge

- When mpox cases were reported in the Democratic Republic of the Congo, FIND worked with partners to evaluate rapid tests under field conditions—identifying which tools were reliable enough for use and where further development was needed.
- In Benin, FIND applied the same rapid-response approach to assess a portable blood culture system designed for hot, resource-limited settings, helping advance faster detection of dangerous bloodstream infections.
- These investments strengthened outbreak readiness while accelerating access to diagnostic tools suited to the communities that need them most. FIND in collaboration with key partners was able to generate the real-world evidence needed for faster, better-informed diagnostic decisions during emerging health threats.





Clinical evidence that moves diagnostics from innovation to impact

In 2025, FIND supported 20 clinical studies across TB, NCDs, pandemic threats, NTDs, AMR, women's health, malaria and fever, and HIV/hepatitis. Each study was designed to address a practical barrier to access – generating the evidence needed for regulatory review, WHO guidance, manufacturer submissions, and country adoption of reliable diagnostics.

Accelerating better TB detection

Seven TB studies were completed. Through the FEND-TB trials, FIND generated evidence on early-stage molecular point-of-care diagnostics for adults, children, and people at risk of drug-resistant TB.

The findings were submitted to WHO and informed its 2025 review of nucleic acid amplification tests. Four additional studies assessed computer-aided detection software for chest X-rays; this evidence supported WHO's June 2025 approval of six tools for TB screening – helping countries to identify people with TB earlier and more efficiently.


Expanding access to quality diabetes care

In Cambodia, Colombia, and Nigeria, FIND evaluated blood glucose meters and point-of-care HbA1c devices and shared the data with manufacturers to support WHO prequalification submissions. Through the ACCEDE initiative, operational research in Kenya and South Africa also produced country-specific evidence on continuous glucose monitoring for type 1 diabetes.

The results are informing national policy and have already contributed to the first continuous glucose monitoring devices becoming available in public-sector clinics in both countries.

Strengthening preparedness for emerging threats

During the mpox response in the Democratic Republic of the Congo, FIND assessed antigen rapid diagnostic tests and found high specificity but insufficient sensitivity. This timely evidence clarified the limitations of current products and the need for better-performing tools. In Uganda, FIND completed preparations to evaluate three molecular point-of-care devices, positioning the programme to begin enrolment in early 2026.



Making antimicrobial resistance testing accessible in low-resource settings


A field evaluation in Benin showed that a “tropicalized” blood culture system was suitable for hospital use under challenging conditions. FIND also launched studies in South Africa and Papua New Guinea on lateral flow assays for sexually transmitted infections using self-collected samples.


Together, these studies are assessing not only diagnostic performance, but also acceptability and usability among pregnant, symptomatic, and asymptomatic users—evidence that is essential for effective scale-up.

Advancing integrated self-testing

Findings from the LIVES study on multi-disease self-testing for HIV, hepatitis B, and hepatitis C were disseminated in 2025. High user acceptability helped inform a WHO technical consultation, strengthening the evidence base for more convenient, person-centred testing models.

In Nigeria, FIND also prepared an evaluation of a dual HIV/hepatitis C rapid diagnostic test, with testing planned for early 2026.





Protecting progress against neglected tropical diseases

In Kenya, FIND evaluated rapid tests for visceral leishmaniasis after discontinuation of the WHO-recommended IT-Leish test, generating urgently needed evidence for national diagnostic policy.

A related study identified the costs and service-delivery requirements of decentralized care models, helping define scalable approaches to improve testing, treatment completion, and progress towards elimination. An evaluation done in Kenya and the Philippines of schistosomiasis rapid tests was also completed; the findings are guiding the design of improved diagnostics and will be shared through a forthcoming publication.



Building the next pipeline of evidence

FIND initiated a clinical evaluation of the Bioneer Q-RFIA assay at the end of 2025 and the beginning of 2026 to assess its performance for detecting drug-resistant TB.

The Malaria and Fever team also started a study in Gondar, Ethiopia, on a non-invasive malaria diagnostic that detects volatile organic compounds, with implementation scheduled to begin in early 2026.



Evidence of demand – and the cost of interrupted funding

The human papillomavirus (HPV) self-sampling transport study in Bangladesh, Kenya, and South Africa enrolled 52% of its target population before it was paused because of funding constraints. Interim findings indicate that dry transport is feasible and could expand access to cervical cancer screening.

Completing the study would allow this promising evidence to be translated into stronger implementation guidance.

FIND's specimen bank: accelerating the next generation of diagnostic tests

FIND's specimen bank gives diagnostic developers access to quality-assured biospecimens and shared infrastructure that no single organization could easily build alone.


The specimen bank has **more than 400,000 well-characterized biological specimens** that enables researchers and product developers to design, validate and improve tests for major health threats.

In 2025, FIND provided **1,241 specimens to 23 organizations for diagnostic research**, development and validation.


The materials supported work on TB, febrile illnesses, COVID-19, Lassa fever and AMR, and included urine, blood, plasma, sputum, serum, antibodies, antigens and culture isolates. FIND's broader collection spans priority disease areas including TB, malaria, COVID-19, hepatitis C, Lassa fever, mpox and AMR.

By providing access to high-quality specimens, FIND reduces the cost, time and complexity of collecting new samples for every study – helping promising diagnostics move faster from development towards use in the communities that need them.

SAMPLES HELD IN FIND'S DIAGNOSTIC SAMPLE BANK, BY DISEASE (2025)




FIND's collection of more than 400,000 well-documented biological samples help researchers worldwide develop and test new diagnostic tools.



FIND's continued efforts to strengthen essential diagnostic lists

FIND supported the Governments of Ethiopia and Indonesia in finalizing their national essential diagnostic lists (NEDLs) and partnered with the African Society for Laboratory Medicine (ASLM) to support the Governments of Cameroon and São Tomé and Príncipe in finalizing their NEDLs.



In 2025, FIND partnered with the Pan American Health Organization (PAHO), with participation from WHO, to help countries across Latin America strengthen NEDLs. Through this regional webinar, the partners provided practical guidance on adopting and implementing NEDLs – an important tool for prioritizing high-impact tests, directing resources where they are needed most, and expanding equitable access to quality diagnostics at every level of the health system.

Diagnostic network optimization and digital tools



FIND supported DNO exercises in three countries (Bangladesh, Indonesia and India) to improve the efficiency, accessibility, equity, and sustainability of TB and integrated diagnostic laboratory networks using FIND-developed tools, including OptiDx and DxGeoMap. In addition, FIND initiated DNO analyses in Laos and Cambodia to inform the design of integrated sample transport systems.

FIND also continued to build country capacity in DNO and related tools across 12 countries in Africa, Latin America, and Southeast Asia. At the global level, FIND partnered with WHO, the Global Laboratory Initiative, Stop TB and the Global Fund to develop guidance for countries on the stepwise implementation of DNO.

Further, FIND initiated the development of an AI-driven DNO tool to support faster analysis, improve interpretation of DNO outputs, and reduce reliance on expert modellers, thereby empowering countries to undertake DNO independently and strengthen country ownership and uptake.

Expanding access for underserved populations

In Kenya, FIND worked with partners to reach more than 24,000 women and girls across 44 counties – including adolescent girls, refugees, older women and women living with disabilities – to understand the barriers they face in accessing health testing. Their input is now shaping new, more equitable health policies.

New portable tests are being developed for diseases like schistosomiasis and visceral leishmaniasis, designed specifically to reach out-of-school children and people in remote areas who are usually missed by hospital- or school-based testing.


FIND is exploring simpler, more private self-testing options – for example, self-collected samples for cervical cancer and sexually transmitted infection screening – to help reach women who may otherwise avoid testing due to cultural or personal sensitivities.

Technical support was also provided to improve TB screening among Indigenous communities in Canada, reflecting FIND's commitment to reaching under-served groups everywhere.

A diagnostic test that is only accessible to people able to travel to a major urban hospital does not address the access gap FIND was established to close.

Much of FIND's work in 2025 focused on reaching populations that are too often underserved, including women, remote rural communities, people affected by stigma, and people living in settings with limited health infrastructure.







Strengthening the capacity of health workers

FIND's online Training Academy equipped 850 learners with practical skills in laboratory quality systems, biosafety and infection control – helping to strengthen the foundations for safe, reliable testing.


The training enabled hands-on capacity building in Kenya and Malawi. In Malawi, nearly 200 staff from the Ministry of Health – representing all 28 districts – were trained in safer procedures for transporting patient samples.

In Kenya, FIND helped design and roll out a digital sample-tracking system linking clinics and laboratories, and also trained local trainers, health officials and county staff to manage it day to day. Together, these investments are building sustainable local capacity so that diagnostic innovations can reach patients reliably and at scale.



Advocating for stronger diagnostic systems worldwide

FIND through its engagement with governments, regional bodies and global health partners, kept diagnostics visible in major policy discussions and strengthened the partnerships needed to expand equitable access.



FIND through its engagement with governments, regional bodies and global health partners, kept diagnostics visible in major policy discussions and strengthened the partnerships needed to expand equitable access.

FIND leadership met with representatives from governments, parliament, technical partners and civil society organizations, on visits to the United Kingdom, United States, Canada and European Union. These discussions raised the profile of diagnostics in policy and funding debates, renewed strategic relationships, and generated follow-up requests and expressions of interest for near-term collaboration.

G20
SOUTH AFRICA 2025





FIND'S ENGAGEMENT AT THE G20 IN SOUTH AFRICA

Under South Africa's 2025 G20 Presidency, FIND contributed to all the Health Working Group meetings and engaged with Member States and international partners. Its advocacy helped position diagnostics within discussions on pandemic preparedness, AMR, universal health coverage, NCDs and TB. FIND also co-hosted Dive into Diagnostics with the Council for Scientific and Industrial Research and the South African Presidency, showcasing innovations from Africa, Asia and Latin America. FIND was subsequently invited to the G20 Health Ministers' Meeting, where the organization led a discussion on financing universal health coverage.

OPENING A PATHWAY TO GREATER INVESTMENT IN ASIA AND THE PACIFIC

FIND formalized a strategic partnership with the Asian Development Bank to expand access to quality diagnostics, strengthen laboratories and regional manufacturing, support responsible digital health adoption, and improve disease surveillance. The partnership creates a platform for diagnostics to be integrated into broader health-system and pandemic-preparedness investments.

BUILDING REGIONAL COLLABORATION IN SOUTHEAST ASIA

FIND opened formal dialogue with the ASEAN Secretariat on priorities under ASEAN Health Cluster 3. Leadership discussions led to work on a concept note and expression of intent for a future partnership. FIND also contributed technical expertise to ASEAN consultations on a regional laboratory network, supporting stronger and more connected laboratory systems across Member States.

MOVING THE PAHO PARTNERSHIP TOWARDS DELIVERY

FIND and the PAHO refined a joint work plan to identify diagnostic access gaps, strengthen regional manufacturing and improve laboratory systems across the Americas. Technical work covered AMR, NTDs, malaria, pandemic threats, NCD diseases and women's health. FIND also contributed to a Member State briefing on diabetes and co-hosted a global webinar on essential diagnostics lists. These activities produced a joint proposal of work for 2026.



MOBILIZING DIPLOMATIC SUPPORT FOR DIAGNOSTICS


FIND engaged representatives from 34 Geneva-based missions and hosted ambassadors from 26 African countries and the African Union. Discussions focused on South–South collaboration, pandemic preparedness, essential diagnostics lists, noncommunicable diseases and sustainable financing. The engagement built support for stronger regional manufacturing and reinforced collaboration with African Union institutions and Africa CDC.



SUSTAINING POLITICAL MOMENTUM AFTER THE WORLD HEALTH ASSEMBLY RESOLUTION

In May 2025, FIND convened its third Diagnostics Day event alongside the 78th World Health Assembly, two years after the adoption of the landmark resolution on diagnostics. Ministers of Health from Indonesia and Uganda, global health leaders and technical partners reviewed progress, shared country experience and identified priorities for closing diagnostic gaps. Discussions addressed equitable access, women's health, pandemic preparedness, national implementation and innovative financing. The event maintained high-level attention on diagnostics and helped shape the agenda for action in 2026.

Across these activities, FIND's objective remained consistent: to ensure that reliable testing is embedded in government planning for both future health emergencies and routine healthcare delivery.



2025 milestones at a glance

MAY 2025

FIND convened its third **Diagnostics Day** alongside the World Health Assembly in Geneva.

JUNE 2025

The WHO approved **six computer-assisted tools** for TB screening, informed by evidence FIND helped generate.

JULY 2025

Kenya officially **eliminated sleeping sickness** (HAT) as a public health problem; FIND signed a new partnership with the Asian Development Bank.

Earlier in 2025, Guinea also achieved **elimination of sleeping sickness** as a public health problem.

THROUGHOUT THE YEAR

850 people completed training through FIND's online Training Academy; new hands-on training reached health workers in Kenya and Malawi.


THROUGHOUT THE YEAR

More than 51 million FIND-supported diagnostic tests were distributed worldwide, across TB, HIV, malaria, COVID-19, sleeping sickness and other diseases.



FIND is headquartered in Geneva, Switzerland, with regional offices in Cape Town (South Africa), Hà Nôi (Viet Nam), Jakarta (Indonesia), Nairobi (Kenya), and New Delhi (India). From these hubs, FIND and its partners carried out research, training and evaluation activities in dozens of countries throughout 2025, spanning Africa, Asia, Latin America and the Pacific.

In 2025, FIND supported research studies, evaluations and country programmes in Australia, Austria, Bangladesh, Brazil, Cambodia, Cameroon, Ethiopia, The Gambia, Indonesia, Kenya, Laos, Lebanon, Malawi, the Netherlands, Nigeria, Papua New Guinea, Peru, the Philippines, Senegal, South Africa, Tanzania, Uganda, Ukraine, Viet Nam and Zambia, among others. People in dozens of additional countries also benefited as FIND-supported products reached their local health systems.



Lessons from 2025: priorities for greater impact in 2026

PRIORITIES

The experience of 2025 highlighted several clear priorities:

- Strong local partnerships are essential. The most effective programmes were built on trusted relationships with national governments, local, regional and global partners, manufacturers and communities.
- Reaching underserved populations requires deliberate engagement. New tools are more likely to succeed when communities and health workers are involved from the outset, rather than when consulted only after development is complete.
- Global health funding is becoming less predictable. In 2025, FIND – like many organizations in the sector – adapted to a more constrained funding environment by making careful choices about priorities while protecting the programmes with the greatest impact for patients and affected communities.
- Emerging technologies offer new opportunities. Artificial intelligence can help analyse health data and support the design of more effective diagnostic networks. It must be introduced responsibly, with local ownership and capacity-building at the centre.

In 2026, FIND will apply these lessons while remaining focused on its core mission: ensuring that everyone can access a reliable diagnosis, wherever they live.

Thank you to all our donors and partners

AFENET
Asian Development Bank
Cisco Systems India
CRDF Global
Dutch Ministry of Foreign Affairs (DGIS), Netherlands
European Union
FioTec
Gates Foundation
Gates Medical Research Institute
Gilead Sciences, Inc
Google.org Giving via FPL (Froncort. AI Private Limited)
India Health Action Trust
MMV
Ministry of Health, Mongolia
National Institutes of Health, USG via CRDF Global
Patrick J. McGovern Foundation
Permanent Mission of Kuwait
Right Fund via Bioneer
Siemens Healthineers
The Global Fund to Fight AIDS, Tuberculosis and Malaria
The Leona M. and Harry B. Helmsley Charitable Trust
The State Secretariat for Education, Research and Innovation (SERI)
Unitaid
US Centers for Disease Control and Prevention via University of Southern California (USC)
US Department of State via JSI Research & Training





FIND
Diagnosis for all

Activity report 2025

Chemin du Pommier 40
1218 Grand-Saconnex, Switzerland

www.finddx.org